✦ LIBER ✦

Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation

✍ Scribed by Cheng-Yuan Peng; Chih-Bin Chen; Hsueh-Chou Lai; Wen-Pang Su; Po-Heng Chuang; Hong-Dar Isaac Wu; Long-Bin Jeng

Book ID: 107593918
Publisher: Springer-Verlag
Year: 2010
Tongue: English
Weight: 188 KB
Volume: 5
Category: Article
ISSN: 1936-0533
DOI: 10.1007/s12072-010-9227-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term lamivudine therapy for childre

Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B

✍ Etienne M. Sokal; Deirdre A. Kelly; Jacek Mizerski; Isabel B. Badia; Jorge A. Ar 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 1 views

One year of lamivudine treatment results in increased hepatitis B e antigen (HBeAg) seroconversion and serum hepatitis B virus (HBV) DNA negativity in children with chronic hepatitis B and high serum alanine aminotransferase concentrations. Two hundred seventy-six children who participated in a 1-ye

Acute exacerbation in chronic type B hep

Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody-positive patients

✍ Yun-Fan Liaw; Dar-In Tai; Chia-Ming Chu; Chia C. Pao; Tong-Jong Chen 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 395 KB 👁 1 views

The incidence, clinicopathological features and etiolo'gy of acute exacerbation occurring in patients with chronic type B hepatitis were 888e88ed prospectively among 385 patients who had HBeAg and 279 who had anti-HBe in serum. During an average follow-up of 23.5 months, acute exacerbations occurred

HBeAg and hepatitis B virus DNA as outco

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

✍ Michael W. Fried; Teerha Piratvisuth; George K. K. Lau; Patrick Marcellin; Wan-C 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 414 KB 👁 2 views

The aims of this study were to evaluate the usefulness of quantitative hepatitis B e antigen (HBeAg) values for predicting HBeAg seroconversion in patients treated with peginterferon alfa-2a and to assess the dynamic changes in quantitative HBeAg during therapy, compared with conventional measures o

Loss of HBsAg antigen during treatment w

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

✍ R. G. Gish; T.-T. Chang; C.-L. Lai; R. De Man; A. Gadano; F. Poordad; J. Yang; H 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB

Efficacy of lamivudine re-treatment for

Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B

✍ J. W. Shin; N. H. Park; J. H. Park; J. H. Park; I. D. Jeong; S-J. Bang; K. R. Jo 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

Comparison of interferon and lamivudine

Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B

✍ Yasuji Arase; Kenji Ikeda; Fumitaka Suzuki; Yoshiyuki Suzuki; Masahiro Kobayashi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

## Abstract The aim of this study was to elucidate the long‐term outcome after interferon (IFN) or lamivudine (LMV) treatment in Japanese patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis B. Inclusion criteria were biopsy proven chronic hepatitis or liver cirrhosis, no history